In his latest Forbes article, WBB Securities President Dr Steve Brozak examines a fundamental challenge facing the U.S. healthcare system: how to appropriately value medical innovation.
Read More about What Price Healthcare? RevMed’s Rasonque—The US Drug Pricing ParadoxWBB Securities is pleased to share Dr. Steve Brozak’s latest Forbes article examining Warren Buffett’s recent observations about speculation in today’s financial markets and what they mean for biotechnology investing.
Read More about New Forbes Article by Dr. Steve Brozak — Is Warren Buffett’s Stock Gambling Warning Bad for Biotechnology?In his latest Forbes review, Dr. Steve Brozak examines The Code as Witness by Dr. Steven Quay and the broader questions it raises about scientific accountability, public trust, biotechnology, and future pandemic preparedness.
Read More about Dr. Steve Brozak Reviews The Code as Witness in ForbesWBB Securities President Dr. Steve Brozak examines the growing concerns surrounding the 2026 Ebola outbreak, including institutional distrust, attacks on healthcare infrastructure, delayed containment efforts, and the broader implications for global public health preparedness.
Read More about Deaths, Burned Clinics—What’s Different About Ebola’s 2026 Return? – Published in ForbesWBB Securities President Dr. Steve Brozak examines five urgent questions emerging from the WHO’s emergency Hantavirus meeting, including transmission risks, global preparedness, and the broader implications for public health systems in a post-pandemic environment.
Read More about 5 Urgent Questions After The WHO Emergency Hantavirus Meeting – Published in ForbesIn a recent Forbes article, Dr. Steve Brozak examines HHS Secretary Robert F. Kennedy Jr.’s focus on the mental health crisis and the growing concern around psychiatric overprescribing.
Read More about Our Mental Health Crisis: RFK Jr. Faces Psychiatric Over-Prescribing – Published in Forbes